Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Hydrogen ion concentration differentiates effects of methamphetamine and dopamine on transporter-mediated efflux.

Wilhelm CJ, Johnson RA, Eshleman AJ, Janowsky A.

J Neurochem. 2006 Feb;96(4):1149-59. Epub 2006 Jan 17.

2.

Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system.

Wilhelm CJ, Johnson RA, Lysko PG, Eshleman AJ, Janowsky A.

J Pharmacol Exp Ther. 2004 Sep;310(3):1142-51. Epub 2004 Apr 21.

3.

[3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux.

Johnson RA, Eshleman AJ, Meyers T, Neve KA, Janowsky A.

Synapse. 1998 Sep;30(1):97-106.

PMID:
9704886
4.

Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis.

Guillot TS, Shepherd KR, Richardson JR, Wang MZ, Li Y, Emson PC, Miller GW.

J Neurochem. 2008 Sep;106(5):2205-17. doi: 10.1111/j.1471-4159.2008.05568.x. Epub 2008 Jul 15.

5.

N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.

Torres B, Ruoho AE.

Neuroscience. 2014 Feb 14;259:194-202. doi: 10.1016/j.neuroscience.2013.11.059. Epub 2013 Dec 7.

6.

Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.

Nickell JR, Krishnamurthy S, Norrholm S, Deaciuc G, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP.

J Pharmacol Exp Ther. 2010 Feb;332(2):612-21. doi: 10.1124/jpet.109.160275. Epub 2009 Oct 23.

7.

Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity.

Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE.

Synapse. 2009 Feb;63(2):147-51. doi: 10.1002/syn.20580.

8.

Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.

Chu PW, Hadlock GC, Vieira-Brock P, Stout K, Hanson GR, Fleckenstein AE.

J Neurochem. 2010 Oct;115(2):325-32. doi: 10.1111/j.1471-4159.2010.06922.x. Epub 2010 Aug 25.

10.

Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter.

Cameron KN, Kolanos R, Solis E Jr, Glennon RA, De Felice LJ.

Br J Pharmacol. 2013 Apr;168(7):1750-7. doi: 10.1111/bph.12061.

11.

Substituted methcathinones differ in transporter and receptor interactions.

Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A.

Biochem Pharmacol. 2013 Jun 15;85(12):1803-15. doi: 10.1016/j.bcp.2013.04.004. Epub 2013 Apr 10.

12.

Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo.

Goodwin JS, Larson GA, Swant J, Sen N, Javitch JA, Zahniser NR, De Felice LJ, Khoshbouei H.

J Biol Chem. 2009 Jan 30;284(5):2978-89. doi: 10.1074/jbc.M805298200. Epub 2008 Dec 1.

13.

Methamphetamine self-administration acutely decreases monoaminergic transporter function.

McFadden LM, Stout KA, Vieira-Brock PL, Allen SC, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE.

Synapse. 2012 Mar;66(3):240-5. doi: 10.1002/syn.21506. Epub 2011 Dec 13.

14.

Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation.

Hadlock GC, Chu PW, Walters ET, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2010 Oct;335(1):207-12. doi: 10.1124/jpet.110.166660. Epub 2010 Jul 9.

15.

An N-terminal threonine mutation produces an efflux-favorable, sodium-primed conformation of the human dopamine transporter.

Fraser R, Chen Y, Guptaroy B, Luderman KD, Stokes SL, Beg A, DeFelice LJ, Gnegy ME.

Mol Pharmacol. 2014 Jul;86(1):76-85. doi: 10.1124/mol.114.091926. Epub 2014 Apr 21.

16.

Lobeline effects on tonic and methamphetamine-induced dopamine release.

Wilhelm CJ, Johnson RA, Eshleman AJ, Janowsky A.

Biochem Pharmacol. 2008 Mar 15;75(6):1411-5. doi: 10.1016/j.bcp.2007.11.019. Epub 2007 Dec 4.

17.

Alterations in the striatal dopamine system during intravenous methamphetamine exposure: effects of contingent and noncontingent administration.

Laćan G, Hadamitzky M, Kuczenski R, Melega WP.

Synapse. 2013 Aug;67(8):476-88. doi: 10.1002/syn.21654. Epub 2013 Mar 19.

18.

Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux.

Binda F, Dipace C, Bowton E, Robertson SD, Lute BJ, Fog JU, Zhang M, Sen N, Colbran RJ, Gnegy ME, Gether U, Javitch JA, Erreger K, Galli A.

Mol Pharmacol. 2008 Oct;74(4):1101-8. doi: 10.1124/mol.108.048447. Epub 2008 Jul 10.

19.

Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.

Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2002 Mar;300(3):1093-100.

Supplemental Content

Support Center